|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLT8D1 |
Gene summary for GLT8D1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLT8D1 | Gene ID | 55830 |
| Gene name | glycosyltransferase 8 domain containing 1 | |
| Gene Alias | AD-017 | |
| Cytomap | 3p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R313 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55830 | GLT8D1 | LZE24T | Human | Esophagus | ESCC | 1.57e-16 | 4.59e-01 | 0.0596 |
| 55830 | GLT8D1 | P2T-E | Human | Esophagus | ESCC | 1.28e-28 | 4.72e-01 | 0.1177 |
| 55830 | GLT8D1 | P4T-E | Human | Esophagus | ESCC | 2.03e-32 | 7.20e-01 | 0.1323 |
| 55830 | GLT8D1 | P5T-E | Human | Esophagus | ESCC | 1.76e-04 | 2.03e-01 | 0.1327 |
| 55830 | GLT8D1 | P8T-E | Human | Esophagus | ESCC | 1.25e-22 | 3.27e-01 | 0.0889 |
| 55830 | GLT8D1 | P9T-E | Human | Esophagus | ESCC | 1.90e-08 | 3.15e-01 | 0.1131 |
| 55830 | GLT8D1 | P10T-E | Human | Esophagus | ESCC | 1.85e-31 | 5.04e-01 | 0.116 |
| 55830 | GLT8D1 | P11T-E | Human | Esophagus | ESCC | 2.76e-22 | 6.67e-01 | 0.1426 |
| 55830 | GLT8D1 | P12T-E | Human | Esophagus | ESCC | 1.41e-33 | 6.01e-01 | 0.1122 |
| 55830 | GLT8D1 | P15T-E | Human | Esophagus | ESCC | 1.15e-18 | 3.30e-01 | 0.1149 |
| 55830 | GLT8D1 | P16T-E | Human | Esophagus | ESCC | 6.30e-31 | 4.87e-01 | 0.1153 |
| 55830 | GLT8D1 | P17T-E | Human | Esophagus | ESCC | 1.25e-09 | 4.26e-01 | 0.1278 |
| 55830 | GLT8D1 | P19T-E | Human | Esophagus | ESCC | 2.87e-12 | 8.08e-01 | 0.1662 |
| 55830 | GLT8D1 | P20T-E | Human | Esophagus | ESCC | 1.96e-14 | 2.82e-01 | 0.1124 |
| 55830 | GLT8D1 | P21T-E | Human | Esophagus | ESCC | 1.93e-27 | 5.82e-01 | 0.1617 |
| 55830 | GLT8D1 | P22T-E | Human | Esophagus | ESCC | 4.91e-20 | 3.98e-01 | 0.1236 |
| 55830 | GLT8D1 | P23T-E | Human | Esophagus | ESCC | 3.08e-24 | 5.82e-01 | 0.108 |
| 55830 | GLT8D1 | P24T-E | Human | Esophagus | ESCC | 2.70e-26 | 5.27e-01 | 0.1287 |
| 55830 | GLT8D1 | P26T-E | Human | Esophagus | ESCC | 1.53e-34 | 6.14e-01 | 0.1276 |
| 55830 | GLT8D1 | P27T-E | Human | Esophagus | ESCC | 6.31e-24 | 4.23e-01 | 0.1055 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLT8D1 | SNV | Missense_Mutation | rs749077355 | c.628C>T | p.Arg210Cys | p.R210C | Q68CQ7 | protein_coding | deleterious(0.01) | probably_damaging(0.95) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLT8D1 | SNV | Missense_Mutation | c.865N>G | p.Leu289Val | p.L289V | Q68CQ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GLT8D1 | SNV | Missense_Mutation | c.392N>C | p.Lys131Thr | p.K131T | Q68CQ7 | protein_coding | tolerated(0.57) | benign(0.062) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| GLT8D1 | SNV | Missense_Mutation | rs201758107 | c.167N>A | p.Arg56Gln | p.R56Q | Q68CQ7 | protein_coding | tolerated(0.76) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLT8D1 | SNV | Missense_Mutation | novel | c.379N>G | p.Asn127Asp | p.N127D | Q68CQ7 | protein_coding | tolerated(0.4) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLT8D1 | SNV | Missense_Mutation | c.1057G>T | p.Asp353Tyr | p.D353Y | Q68CQ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| GLT8D1 | SNV | Missense_Mutation | novel | c.979N>T | p.Leu327Phe | p.L327F | Q68CQ7 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GLT8D1 | SNV | Missense_Mutation | novel | c.287N>G | p.Ile96Ser | p.I96S | Q68CQ7 | protein_coding | deleterious(0.04) | benign(0.037) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| GLT8D1 | SNV | Missense_Mutation | rs755520175 | c.688C>T | p.Arg230Cys | p.R230C | Q68CQ7 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| GLT8D1 | SNV | Missense_Mutation | c.710N>A | p.Ser237Asn | p.S237N | Q68CQ7 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |